In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and Gram-positive cocci
Sparfloxacin (AT-4140 and CI-978) was evaluated for activity against 194 clinical isolates of staphylococci, streptococci, Enterococcus faecalis, anaerobic Gram-positive cocci, and Haemophilus sp. The MIC of sparfloxacin for >93% of the strains tested was ⩽0.5 μg/ml. Sparfloxacin demonstrated inc...
Gespeichert in:
| Veröffentlicht in: | Diagnostic microbiology and infectious disease 1991-07, Vol.14 (4), p.355-360 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 360 |
|---|---|
| container_issue | 4 |
| container_start_page | 355 |
| container_title | Diagnostic microbiology and infectious disease |
| container_volume | 14 |
| creator | Rudrik, James T. Ferrigno, Susanne R. Gee, Sharon L. |
| description | Sparfloxacin (AT-4140 and CI-978) was evaluated for activity against 194 clinical isolates of staphylococci, streptococci,
Enterococcus faecalis, anaerobic Gram-positive cocci, and
Haemophilus sp. The MIC of sparfloxacin for >93% of the strains tested was ⩽0.5
μg/ml. Sparfloxacin demonstrated increased activity against enterococci, staphylococci, pneumococci, and anaerobic cocci when compared with ciprofloxacin. |
| doi_str_mv | 10.1016/0732-8893(91)90028-E |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72089254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>073288939190028E</els_id><sourcerecordid>72089254</sourcerecordid><originalsourceid>FETCH-LOGICAL-c272t-56b72079d967d866fc00c4836cf4793531c2f0e31686a44f9d9f13bba48af25e3</originalsourceid><addsrcrecordid>eNp9kd9uFCEUxonR1O2fN9CEK9MmosCwA9yYNJu13aSJN_WaMMyhYmZgCjPVvoGPXbbb6J1XnPD9zndyvoPQO0Y_Mcraz1Q2nCilm3PNLjSlXJHtK7RiSmpCqaSv0eov8hYdl_KTUsa1oEfoiNVPptoV-rOL-CHMOWHr5lCrR5w8LpPNfki_rQsRn1_eEsEExTb2eLMjWqqLj9jiCL_w_RJiGlKEKs5hDC6nLtgB2zuIc4XubIhlxtcWxjT9CMNSnl2ush3JlEqoIwG75Fw4RW-8HQqcvbwn6PvX7e3mmtx8u9ptLm-I45LPZN12klOpe93KXrWtd5Q6oZrWeSF1s26Y455Cw1rVWiF8BT1rus4KZT1fQ3OCPhx8p5zuFyizGUNxMAw2QlqKqe5K87WooDiAdadSMngz5TDa_GgYNfsDmH26Zp-u0cw8H8Bsa9v7F_-lG6H_13RIvOpfDjrUJR8CZFNcgOigDxncbPoU_j_gCel8lBA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72089254</pqid></control><display><type>article</type><title>In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and Gram-positive cocci</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rudrik, James T. ; Ferrigno, Susanne R. ; Gee, Sharon L.</creator><creatorcontrib>Rudrik, James T. ; Ferrigno, Susanne R. ; Gee, Sharon L.</creatorcontrib><description>Sparfloxacin (AT-4140 and CI-978) was evaluated for activity against 194 clinical isolates of staphylococci, streptococci,
Enterococcus faecalis, anaerobic Gram-positive cocci, and
Haemophilus sp. The MIC of sparfloxacin for >93% of the strains tested was ⩽0.5
μg/ml. Sparfloxacin demonstrated increased activity against enterococci, staphylococci, pneumococci, and anaerobic cocci when compared with ciprofloxacin.</description><identifier>ISSN: 0732-8893</identifier><identifier>EISSN: 1879-0070</identifier><identifier>DOI: 10.1016/0732-8893(91)90028-E</identifier><identifier>PMID: 1889186</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>4-Quinolones ; Anti-Bacterial Agents - pharmacology ; Anti-Infective Agents - pharmacology ; Fluoroquinolones ; Gram-Positive Bacteria - drug effects ; Haemophilus - drug effects ; Humans ; Microbial Sensitivity Tests ; Staphylococcus - drug effects ; Streptococcus - drug effects ; Vancomycin - pharmacology</subject><ispartof>Diagnostic microbiology and infectious disease, 1991-07, Vol.14 (4), p.355-360</ispartof><rights>1991</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c272t-56b72079d967d866fc00c4836cf4793531c2f0e31686a44f9d9f13bba48af25e3</citedby><cites>FETCH-LOGICAL-c272t-56b72079d967d866fc00c4836cf4793531c2f0e31686a44f9d9f13bba48af25e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/073288939190028E$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1889186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rudrik, James T.</creatorcontrib><creatorcontrib>Ferrigno, Susanne R.</creatorcontrib><creatorcontrib>Gee, Sharon L.</creatorcontrib><title>In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and Gram-positive cocci</title><title>Diagnostic microbiology and infectious disease</title><addtitle>Diagn Microbiol Infect Dis</addtitle><description>Sparfloxacin (AT-4140 and CI-978) was evaluated for activity against 194 clinical isolates of staphylococci, streptococci,
Enterococcus faecalis, anaerobic Gram-positive cocci, and
Haemophilus sp. The MIC of sparfloxacin for >93% of the strains tested was ⩽0.5
μg/ml. Sparfloxacin demonstrated increased activity against enterococci, staphylococci, pneumococci, and anaerobic cocci when compared with ciprofloxacin.</description><subject>4-Quinolones</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Infective Agents - pharmacology</subject><subject>Fluoroquinolones</subject><subject>Gram-Positive Bacteria - drug effects</subject><subject>Haemophilus - drug effects</subject><subject>Humans</subject><subject>Microbial Sensitivity Tests</subject><subject>Staphylococcus - drug effects</subject><subject>Streptococcus - drug effects</subject><subject>Vancomycin - pharmacology</subject><issn>0732-8893</issn><issn>1879-0070</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kd9uFCEUxonR1O2fN9CEK9MmosCwA9yYNJu13aSJN_WaMMyhYmZgCjPVvoGPXbbb6J1XnPD9zndyvoPQO0Y_Mcraz1Q2nCilm3PNLjSlXJHtK7RiSmpCqaSv0eov8hYdl_KTUsa1oEfoiNVPptoV-rOL-CHMOWHr5lCrR5w8LpPNfki_rQsRn1_eEsEExTb2eLMjWqqLj9jiCL_w_RJiGlKEKs5hDC6nLtgB2zuIc4XubIhlxtcWxjT9CMNSnl2ush3JlEqoIwG75Fw4RW-8HQqcvbwn6PvX7e3mmtx8u9ptLm-I45LPZN12klOpe93KXrWtd5Q6oZrWeSF1s26Y455Cw1rVWiF8BT1rus4KZT1fQ3OCPhx8p5zuFyizGUNxMAw2QlqKqe5K87WooDiAdadSMngz5TDa_GgYNfsDmH26Zp-u0cw8H8Bsa9v7F_-lG6H_13RIvOpfDjrUJR8CZFNcgOigDxncbPoU_j_gCel8lBA</recordid><startdate>199107</startdate><enddate>199107</enddate><creator>Rudrik, James T.</creator><creator>Ferrigno, Susanne R.</creator><creator>Gee, Sharon L.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199107</creationdate><title>In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and Gram-positive cocci</title><author>Rudrik, James T. ; Ferrigno, Susanne R. ; Gee, Sharon L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c272t-56b72079d967d866fc00c4836cf4793531c2f0e31686a44f9d9f13bba48af25e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>4-Quinolones</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Infective Agents - pharmacology</topic><topic>Fluoroquinolones</topic><topic>Gram-Positive Bacteria - drug effects</topic><topic>Haemophilus - drug effects</topic><topic>Humans</topic><topic>Microbial Sensitivity Tests</topic><topic>Staphylococcus - drug effects</topic><topic>Streptococcus - drug effects</topic><topic>Vancomycin - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rudrik, James T.</creatorcontrib><creatorcontrib>Ferrigno, Susanne R.</creatorcontrib><creatorcontrib>Gee, Sharon L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diagnostic microbiology and infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rudrik, James T.</au><au>Ferrigno, Susanne R.</au><au>Gee, Sharon L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and Gram-positive cocci</atitle><jtitle>Diagnostic microbiology and infectious disease</jtitle><addtitle>Diagn Microbiol Infect Dis</addtitle><date>1991-07</date><risdate>1991</risdate><volume>14</volume><issue>4</issue><spage>355</spage><epage>360</epage><pages>355-360</pages><issn>0732-8893</issn><eissn>1879-0070</eissn><abstract>Sparfloxacin (AT-4140 and CI-978) was evaluated for activity against 194 clinical isolates of staphylococci, streptococci,
Enterococcus faecalis, anaerobic Gram-positive cocci, and
Haemophilus sp. The MIC of sparfloxacin for >93% of the strains tested was ⩽0.5
μg/ml. Sparfloxacin demonstrated increased activity against enterococci, staphylococci, pneumococci, and anaerobic cocci when compared with ciprofloxacin.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>1889186</pmid><doi>10.1016/0732-8893(91)90028-E</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-8893 |
| ispartof | Diagnostic microbiology and infectious disease, 1991-07, Vol.14 (4), p.355-360 |
| issn | 0732-8893 1879-0070 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72089254 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | 4-Quinolones Anti-Bacterial Agents - pharmacology Anti-Infective Agents - pharmacology Fluoroquinolones Gram-Positive Bacteria - drug effects Haemophilus - drug effects Humans Microbial Sensitivity Tests Staphylococcus - drug effects Streptococcus - drug effects Vancomycin - pharmacology |
| title | In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and Gram-positive cocci |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T20%3A07%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20activity%20of%20sparfloxacin%20(AT-4140%20and%20CI-978),%20a%20new%20quinolone%20antimicrobial%20agent,%20against%20Haemophilus%20and%20Gram-positive%20cocci&rft.jtitle=Diagnostic%20microbiology%20and%20infectious%20disease&rft.au=Rudrik,%20James%20T.&rft.date=1991-07&rft.volume=14&rft.issue=4&rft.spage=355&rft.epage=360&rft.pages=355-360&rft.issn=0732-8893&rft.eissn=1879-0070&rft_id=info:doi/10.1016/0732-8893(91)90028-E&rft_dat=%3Cproquest_cross%3E72089254%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72089254&rft_id=info:pmid/1889186&rft_els_id=073288939190028E&rfr_iscdi=true |